Effect of combining an ACE inhibitor and a VDR activator on glomerulosclerosis, proteinuria, and renal oxidative stress in uremic rats

American Journal of Physiology - Renal Physiology

Volumn 302, Issue 1, 2012, Pages 141-149

  Finch, Jane L ^a   Suarez, Edu B ^b,c   Husain, Kazim ^b   Ferder, Leon ^b   Cardema, Michelle C ^d   Glenn, Denis J ^d   Gardner, David G ^d   Liapis, Helen ^a   Slatopolsky, Eduardo ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^c UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ACEI; ANP; eNOS; iNOS; Vitamin D

Indexed keywords

4 HYDROXYNONENAL; ATRIAL NATRIURETIC FACTOR; COPPER ZINC SUPEROXIDE DISMUTASE; CREATININE; ENALAPRIL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; PARATHYROID HORMONE; PARICALCITOL; PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE P22 PHOX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DISEASE COURSE; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME REPRESSION; FEMALE; GENE EXPRESSION REGULATION; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; HYPERTENSION; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RENAL PROTECTION; SYSTOLIC BLOOD PRESSURE; TISSUE LEVEL; UREMIA;

EID: 83455176692     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00293.2011     Document Type: Article

References (58)

1. Akishita M, Nagai K, Xi H, Yu W, Sudoh N, Watanabe T, Ohara- Imaizumi M, Nagamatsu S, Kozaki K, Horiuchi M, Toba K. Reninangiotensin system modulates oxidative stress-induced endothelial cell apoptosis in rats. Hypertension 45:1188 -1193, 2005.
2. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, Light RP, Agarwal R. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 52:249 -255, 2008.
3. Babior BM. NADPH oxidase: an update. Blood 93: 1464-1476, 1999.
4. Benigni A, Zoja C, Corna D, Zatelli C, Conti S, Campana M, Gagliardini E, Rottoli D, Zanchi C, Abbate M, Ledbetter S, Remuzzi G. Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J Am Soc Nephrol 14: 1816-1824, 2003.
5. Brewster IC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 116: 263-272, 2004.
6. Broadbent NV, Stahl PJ, Chen J, Mizrahi M, Lal A, Bozkurt A, Poppas DP, Felsen D. Early upregulation of iNOS mRNA expression and increase in NO metabolites in pressurized renal epithelial cells. Am J Physiol Renal Physiol 293: F1877-F1888, 2007.
7. Conger JD, Falk SA, Yuan BH, Schrier RW. Atrial natriuretic peptide and dopamine in a rat model of ischemic acute renal failure. Kidney Int 35: 1126-1132, 1989.
8. Cozzolino M, Staniforth ME, Liapis H, Finch J, Burke SK, Dusso AS, Slatopolsky E. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 64: 1653-1661, 2003.
9. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomized controlled trial. Lancet 376: 1543-1551, 2010.
10. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 168: 1340-1349, 2008.
11. Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 289: F8-F28, 2005.
12. Forbes MS, Thornhill BA, Park MH, Chevalier RL. Lack of endothelial nitric-oxide synthase leads to progressive focal renal injury. Am J Pathol 170: 877-899, 2007.
13. Fridovich I. Superoxide radical and superoxide dismutases. Annu Rev Biochem 64: 97-112, 1995.
14. Gongora MC, Qin Z, Laude K, Kim HW, McCann L, Folz JR, Dikalov S, Fukai T, Harrison DG. Role of extracellular superoxide dismutase in hypertension. Hypertension 48: 473-481, 2006.
15. Guo Z, Boekhoudt GH, Boss JM. Role of the intronic enhancer in tumor necrosis factor-mediated induction of manganese superoxide dismutase. J Biol Chem 278: 23570-23578, 2003.
16. Han KH, Lim JM, Kim WY, Kim H, Madsen KM, Kim J. Expression of endothelial nitric oxide synthase in developing rat kidney. Am J Physiol Renal Physiol 288: F694-F702, 2005.
17. Hannedouche T, Landais P, Goldfarb B, El Esper N, Fournier A, Godin M, Durand D, Chanard J, Mignon F, Suc JM, Grunfeld JP. Randomized controlled trial of enalapril and beta blockers in nondiabetic chronic renal failure. BMJ 309: 833-837, 1994.
18. Hattori Y, Akimoto K, Gross SS, Hattori S, Kasai K. Angiotensin II-induced oxidative stress elicits hypoadiponectinaemia in rats. Diabetologia 48: 1066-1074, 2005.
19. Heeringa P, van Goor H, Itoh-Lindstrom Y, Maeda N, Falk RJ, Assmann KJ, Kallenberg CG, Jennette JC. Lack of endothelial nitric oxide synthase aggravates murine accelerated anti-glomerular basement membrane glomerulonephritis. Am J Pathol 156: 879-888, 2005.
20. Husain K, Ferder L, Mizobuchi M, Finch JL, Slatopolsky E. Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol 29: 465-472, 2009.
21. Husain K, Suarez E, Isidro A, Ferder L. Effects of paricalcitol and enalapril on atherosclerotic injury in mouse aortas. Am J Nephrol 32: 296-304, 2010.
22. Jacobson HR. Chronic renal failure: pathophysiology. Lancet 338: 419-423, 1991.
23. Kalantar-Zedeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70: 771-780, 2006.
24. Kamper AL, Strandgaard S, Leyssac PP. Effect of enalapril on the progression of chronic renal failure: a randomized controlled trial. Am J Hypertens 5: 423-430, 2002.
25. Koga H, Hagiwara S, Kusaka J, Matsumoto S, Nishida T, Yokoi I, Noguchi T. Human atrial natriuretic peptide attenuates renal ischemiareperfusion injury. J Surg Res [Epub ahead of print].
26. Li VC, Kong J, Wei M. 1,25-Dihydroxyvitamin D3 is a negative endocrine regulator of the renin angiotensin system. J Clin Invest 110: 229-238, 2002.
27. Ling H, Li X, Jha S, Wang W, Karetskaya L, Pratt B, Ledbetter S. Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporine A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Neprol 14: 377-388, 2003.
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2[-delta delta C(T)] method. Methods 25: 402-408, 2001.
29. Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S, Abe H, Kuze K, Fukatsu A, Kita T, Doi T. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 158: 1733-1741, 2001.
30. Marklund SL. Regulation of cytokines of extracellular superoxide dismutase and other superoxide dismutase isozymes in fibroblasts. J Biol Chem 267: 6696-6701, 1992.
31. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334: 939-945, 1996.
32. Mendoza MG, Castillo-Henkel C, Medina-Santillan R, Jarillo Luna RA, Robles HV, Romo E, Rios A, Escalante B. Kidney damage after renal ablation is worsened in endothelial nitric oxide synthase -/- mice and improved by combined administration of L-arginine and antioxidants. Nephrology 13: 218-227, 2008.
33. Michel T, Feron O. Nitric oxide syntheses: which, where, how, and why? J Clin Invest 100: 2146-2152, 1997.
34. Mitaka C, Kudo T, Jibiki M, Sugano N, Inoue Y, Makita K, Imai T. Effects of human atrial natriuretic peptide on renal function in patients undergoing abdominal aortic aneurysm repair. Crit Care Med 36: 745, 2008.
35. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, Slatopolsky E. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 18: 1796-1806, 2007.
36. Na Y, Zhang XX, Zhang XD, Yuan HP, Hu XL, Zheng W, Li G. Effects of reduced glutathione on contents of hydroxyproline and oxidation stress reaction in kidney of unilateral ureteral obstruction in rat. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 12: 735-738, 2007.
37. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin II receptor blocker and angiotensinconverting enzyme inhibitor in nondiabetic renal disease (COOPERATE): a randomized controlled trial. Lancet 361: 117-124, 2003.
38. Nakayama T, Sato W, Kosugi T, Zhang L, Campbell-Thompson M, Yoshimura A, Croker BP, Johnson RJ, Nakagawa T. Endothelial injury due to eNOS deficiency accelerates the progression of chronic renal disease in the mouse. Am J Physiol Renal Physiol 296: F317-F327, 2009.
39. Noiri E, Peresleni T, Miller F, Goligorsky MS. In vitro targeting of inducible NOS with oligodeoxynucleotides protects rat kidney against ischemia. J Clin Invest 97: 2377-2383, 1996.
40. Panichi V, Migliori M, Taccola D, Filippi C, De Nisco L, Giovannini L, Palla R, Tetta C, Camussi G. Effects of 1,25(OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int 60: 87-95, 2001.
41. Peterson JC, Adler S, Burkart JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 123: 754-762, 1995.
42. Read SM, Northcole DH. Minimization of variation in the response to different protein of the Coomassie blue G dye-binding assay for protein. Anal Biochem 116: 53-64, 1981.
43. Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 18: 89-95, 2000.
44. Salo DC, Pacifici RE, Lin SW, Giulivi C, Davies KJ. Superoxide dismutase undergo proteolysis and fragmentation following oxidative modification and inactivation. J Biol Chem 265: 11919-11927, 1990.
45. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 83: 754-759, 2006.
46. Schwartz D, Mendonca M, Schwartz IF, Xia Y, Satriano J, Wilson CB, Blantz RC. Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J Clin Invest 100: 439-448, 1998.
47. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E. Effect of 1,25(OH)2 vitamin D3 on glomerulosclerosis in inftotally nephrectomized rats. Kidney Int 53: 1696-1705, 1998.
48. Sindhu RK, Ehdaie A, Farmand F, Dhaliwal KK, Nguyen T, Zhan CD, Roberts CK, Vaziri ND. Expression of catalase and glutathione peroxidase in renal insufficiency. Biochim Biophys Acta 1743: 86-92, 2005.
49. Somani SM, Husain K, Schlorff E. Response of antioxidant system to physical and chemical stress. In: Oxidants, Antioxidants and Free Radicals, edited by Baskin SI and Salem H. Washington, DC: Taylor and Francis, 1997, p. 125-141.
50. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 17: 3382-3393, 2006.
51. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349: 446-456, 2003.
52. Touyz RM, Tabet F, Schiffrin EL. Redox-dependent signaling by angiotensin II and vascular remodeling in hypertension. Clin Exp Pharmacol Physiol 30: 860-866, 2003.
53. Vaziri ND, Wang XQ, Oveisi F, Rad B. Induction of oxidative stress by glutathione depletion causes severe hypertension in normal rats. Hypertension 36: 142-146, 2000.
54. Vaziri ND, Ni Z, Oveisi F, Trnavsky-Hobbs DL. Effect of antioxidant therapy on blood pressure and NO synthase expression in hypertensive rats. Hypertension 36: 957-964, 2000.
55. Vaziri ND, Ding Y, Ni Z. Compensatory up-regulation of nitric oxide synthase isoforms in lead-induced hypertension; reversal by a superoxide dismutase-mimetic drug. J Pharmacol Exp Ther 298: 679-685, 2001.
56. Yuan W, Pan W, Kong J, Zheng W, Szeto FL, Wong KE, Cohen R, Klopot A, Zhang Z, Li YC. 1,25-Dihydroxyvitamin D3 suppresses renin gene transcription by blocking the activity of the cyclic AMP response element in the renin gene promoter. J Biol Chem 282: 29821-29830, 2007.
57. Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, Taylor WR, Griendling KK. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 32: 488-495, 1998.
58. Zhang L, Ma Y, Zhang J, Cheng J, Du J. A new cellular signaling mechanism for angiotensin II activation of NF-KB: an IKB-independent, RSK-mediated phosphorylation of p65. Arterioscler Thromb Vasc Biol 25: 1148-1153, 2005.